Promising results with the C-RAD GEMini detector

The C-RAD GEMini detector system has been especially designed for VMAT treatments in advanced radiation therapy. The detector will be used both as an imaging and dosimetry device

C-RAD Imaging has during 2013 introduced major improvements of the detector performance. As a result resolution and contrast has been improved.

The new detector has a less complex design and is easier to produce. The system is hermetically sealed and can easily be integrated and mounted on the linac system.

Tests with the new detector has successfully been performed at the University Clinic in Salzburg, Austria. The improvements of the GEMini system has been confirmed in Salzburg. As a result the clinic has released the next payment of the detector. The next phase of the cooperation will be started.

The parties have agreed to introduce one more modification in order to reduce scatter. A patent application of this innovation has been filed in the US. A detector with this innovation included will be tested in a few months.

Tim Thurn, CEO, C-RAD AB:

 “The test results of the new GEMini system for use in the fast growing VMAT market is promising. Projects are running with customers and partners in Europe.”

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 24 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD Sentinel^TM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has acquired 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.

For more information on C-RAD, please visit www.c-rad.com.

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666931, E-mail investors@c-rad.com